Cannabis Law Report

JANUARY 12, 2022

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.”

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

MAY 10, 2022

Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. CBD’s anti-seizure properties, demonstrated through clinical trials, have made it a game-changer in the epilepsy field.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

DECEMBER 1, 2021

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-?), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown in these pre-clinical studies to selectively block TNF-? About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. Senator Anna Wishart (D) has re-introduced legislation, LB 110, to allow qualifying patients with certain debilitating conditions to use and safely access medical cannabis.

Legislation 160

Legislation Decriminalization Access Therapy 160

Cannabis Law Report

NOVEMBER 25, 2021

The Food and Drug Administration (FDA) recently approved the use of CBD to help treat the condition in individuals as young as two years old. Depression and anxiety are serious mental health conditions that should be taken seriously. Chronic Pain.

CBD 52

CBD Clinical Trials Epilepsy Chronic Pain 52

Veriheal

JULY 12, 2021

As a veteran, being able to get past the PTSD involves transitioning out of the mental and emotional war zone, which is challenging and the reason why veterans seek out multiple methods to deal with the condition. A study conducted by Miriam Reisman reported that between 13.5% What Is The Latest Research for Veterans and PTSD?

Treatment 104

Treatment Sleep Clinical Trials Data 104

MMJ Recs

JUNE 15, 2022

Medical marijuana (MMJ) is used to treat pain from a wide variety of conditions or illnesses, including everything from chronic back pain to arthritis. There are many treatments that can be utilized along with MMJ products to alleviate pain, such as medications, physical therapy, and massage.

Patients 52

Patients Treatment Clinical Trials Therapy 52

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Chris Chapman, M.D., About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 16, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “For

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Herb Collective

JUNE 3, 2018

Recent clinical studies support its efficacy in burning fat cells, delaying the onset of chronic disease indicators, treating mental health conditions, and killing bacteria. In fact, it with the number of ailments and chronic conditions that it treats, it’s easy to understand why the product has a wonder drug appeal.

Oil 56

Oil CBD Blood Pressure Chronic Pain 56

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. a driver of chronic inflammation. Dr. Chapman Bio.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., signaling, a key driver of chronic inflammation. Patent 11,219,620 B2, titled “Method of Treating Sarcopenia.”

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Joint Blog

APRIL 17, 2020

But as an older user-base with more complicated medical conditions continue to grow, it is important to understand how THC could adversely impact other co-administered medications. Medical cannabis is typically prescribed for patients with severe conditions including inflammatory conditions (e.g.,

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

NOVEMBER 23, 2021

MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-?), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

CannaTech

MARCH 24, 2019

In particular, research and development for cannabis-based therapies targeting women’s health challenges is making headway. The female reproductive system has the highest concentration of endocannabinoid receptors after the human brain, making it particularly receptive to cannabis-based therapies.

Research and Development 45

Research and Development Therapy Clinical Trials Chronic Pain 45

Puff Puff Post

JANUARY 1, 2020

Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer. With increasing social acceptance more doctors feel comfortable recommending it to treat chronic pain. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Acceptance of Medicinal Cannabis.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

JANUARY 1, 2020

Early studies suggest, and patients confirm, the use of cannabis i n pain management for cancer. With increasing social acceptance more doctors feel comfortable recommending it to treat chronic pain. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain. Acceptance of Medicinal Cannabis.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

The Joint Blog

APRIL 22, 2022

But, if it is consumed along with the right amount of therapy, it might work wonders for PTSD patients. The opioid crisis is a major issue that many Americans suffer from, but many preclinical trials and human clinical trials suggest that CBD might help people reduce their dependence on opioids. Helps Relieve Pain.

Oil 26

Oil CBD Topical Clinical Trials 26

The Cannigma

DECEMBER 12, 2022

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. Now, psychedelic research is booming. 19 20 21 22 23.

History 119

History Microdosing Research and Development Clinical Trials 119

The Cannigma

JUNE 24, 2021

While many health conditions can be treated with more traditional pharmaceuticals, plant-based products may be a safer and healthier option – or at least a safe health supplement. Both THC and CBD rich products may help those suffering from pain lasting several months. Part of a natural, alternative lifestyle.

CBD 75

CBD Microdosing Edibles Sleep 75

Otherside Farms

APRIL 30, 2019

Chronic pain. After several trials with traditional forms of therapy and medication with no long-term effectiveness, researchers decided to give CBD oil a shot. Soon, we may even see some large-scale clinical trials that can eventually replace dangerous mood-disorder medications like Xanax and Prozac.

Oil 70

Oil CBD Blood Pressure Clinical Trials 70

Project CBD

FEBRUARY 27, 2023

No single drug yet exists to address all of the disease’s effects on the body, which can include widespread aches and pains, sleeplessness, fatigue, anxiety, and depression. Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life.

THC 144

THC CBD Sleep Clinical Trials 144

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

OCTOBER 22, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Cannabis oil: TO Pharmaceuticals TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

OCTOBER 18, 2021

The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases. Cannabis oil: TO Pharmaceuticals.

Research and Development 52

Research and Development Pharmaceutical Chronic Pain Therapy 52

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Background. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. government-sponsored scientific research – and to extensive anecdotal accounts from medical marijuana patients – which highlight the potential of cannabinoid-based therapies for TBI.

THC 64

THC CBD Cannabinoids Research and Development 64

The Cannigma

APRIL 8, 2021

The doctor diagnoses the condition and chooses a specific medicine. It’s not a targeted therapy, that’s why it’s so good at symptom relief, but it hasn’t fix much of anything. That there’s not enough information about, there’s not enough clinical trials, and there’s not enough this and that. MSO: Yeah.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. The measure adds anxiety, autism, opioid addiction or dependence, anorexia nervosa, among other qualifying conditions. California. New Hampshire.

Legislation 59

Legislation Patients Access Banking 59